A large retrospective US study with information from over 7.5 million patients with a mean follow-up time of 4.7 years found individuals with psoriasis who received TNF-α inhibitors had a lower risk for major cardiovascular events than those receiving oral/phototherapy or topical therapy [123]. Here, TNF is linked to psoriasis.